Would you recommend adjuvant chemotherapy therapy to a premenopausal patient with ER+ lobular breast cancer who had a partial response to neoadjuvant endocrine therapy?
Does the presence of N1 disease push you towards offering chemotherapy or would you continue endocrine therapy based on the PR?
Thanks for your answer, I will run the PEPI score ...